

# A randomized trial of doxorubicin versus doxorubicin p advanced thyroid carcinoma

Cancer

56, 2155-2160

DOI: [10.1002/1097-0142\(19851101\)56:9<2155::aid-cnrcr2820560903>3.0.co;2-e](https://doi.org/10.1002/1097-0142(19851101)56:9<2155::aid-cnrcr2820560903>3.0.co;2-e)

Citation Report

#	ARTICLE	IF	CITATIONS
1	ecancermedalscience. Ecancermedalscience, 2014, 8, 449.	0.6	8
2	Perusing the literature. Contemporary Clinical Trials, 1986, 7, 165-174.	2.0	0
4	Chemotherapy for thyroid cancer. Radiotherapy and Oncology, 1987, 10, 187-194.	0.3	73
5	Chemotherapy of thyroid carcinoma. Journal of Endocrinological Investigation, 1987, 10, 303-310.	1.8	105
6	Thyroid and Parathyroid Cancer. Clinics in Geriatric Medicine, 1987, 3, 729-742.	1.0	6
7	Metastatic medullary thyroid carcinoma: Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer, 1988, 62, 1899-1903.	2.0	70
8	Papillary and follicular thyroid cancer: Impact of treatment in 1578 patients. International Journal of Radiation Oncology Biology Physics, 1988, 14, 1063-1075.	0.4	271
9	Aclarubicin in advanced thyroid cancer: a phase II study. European Journal of Cancer & Clinical Oncology, 1988, 24, 1271-1275.	0.9	21
10	There is a Benefit from Chemotherapy for Thyroid Cancer. Progress in Surgery, 1988, 19, 163-180.	0.0	3
11	The Place of External Radiation Therapy for Differentiated and Undifferentiated Thyroid Carcinoma. Progress in Surgery, 1988, 19, 147-162.	0.0	2
12	Study of cell kinetics in anaplastic thyroid carcinoma transplanted to nude mice. Journal of Surgical Oncology, 1989, 41, 1-4.	0.8	20
13	The biological characteristics and chemosensitivity of anaplastic thyroid carcinoma transplanted into nude mice. The Japanese Journal of Surgery, 1990, 20, 690-695.	0.2	8
14	Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Journal of Cancer Research and Clinical Oncology, 1990, 116, 21-23.	1.2	93
15	Changing Concepts in the Management of Hereditary and Sporadic Medullary Thyroid Carcinoma. Endocrinology and Metabolism Clinics of North America, 1990, 19, 613-635.	1.2	48
16	Follicular and Hürthle Cell Carcinoma of the Thyroid. Endocrinology and Metabolism Clinics of North America, 1990, 19, 577-591.	1.2	82
17	Chemotherapy in Metastatic Nonanaplastic Thyroid Cancer: Experience at the Institut Gustave-Roussy. Tumori, 1990, 76, 480-483.	0.6	96
19	Long-term Management of Differentiated Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 1990, 19, 719-739.	1.2	38
20	Thyroid Cancer: A Lethal Endocrine Neoplasm. Annals of Internal Medicine, 1991, 115, 133-147.	2.0	220

#	ARTICLE	IF	CITATIONS
22	Combination therapy for anaplastic giant cell thyroid carcinoma. <i>Cancer</i> , 1991, 67, 564-566.	2.0	133
23	Anaplastic Thyroid Carcinoma with Prominent Cardiac Metastasis, Accompanied by a Marked Leukocytosis with a Neutrophilia and High GM-CSF Level in Serum.. <i>Internal Medicine</i> , 1992, 31, 1107-1111.	0.3	35
24	Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a: A study by the Italian trials in Medical Oncology Group. <i>Cancer</i> , 1993, 72, 3099-3105.	2.0	121
25	Medical Therapy for Differentiated Thyroid Carcinoma*. <i>Endocrine Reviews</i> , 1994, 15, 500-515.	8.9	58
26	Ectopic Adrenocorticotrophic Hormone Syndrome. <i>Endocrine Reviews</i> , 1994, 15, 752-787.	8.9	217
27	Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. <i>Cancer</i> , 1994, 73, 432-436.	2.0	131
28	Expression of multidrug resistance-associated protein (MRP) in anaplastic carcinoma of the thyroid. <i>Cancer Letters</i> , 1994, 82, 185-188.	3.2	33
29	Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. <i>Annals of Oncology</i> , 1994, 5, 763-765.	0.6	104
30	Intensive Chemotherapy for Anaplastic Thyroid Carcinoma: Combination of Cisplatin, Doxorubicin, Etoposide and Peplomycin with Granulocyte Colonystimulating Factor Support. <i>Japanese Journal of Clinical Oncology</i> , 1995, 25, 203-207.	0.6	28
31	Anaplastic carcinoma of the thyroid: A 24-year experience. <i>Head and Neck</i> , 1995, 17, 41-48.	0.9	216
33	Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. <i>British Journal of Cancer</i> , 1995, 71, 363-365.	2.9	140
34	Diagnosis and Management of Thyroid Cancer. <i>Cancer Control</i> , 1995, 2, 107327489500200.	0.7	0
35	Thyroid cancer: Different outcomes to chemotherapy according to tumour histology. <i>European Journal of Cancer</i> , 1995, 31, 2423-2424.	1.3	14
36	Expression of multidrug resistance-associated protein (MRP) in thyroid cancers. <i>Cancer Letters</i> , 1995, 95, 135-138.	3.2	30
37	Treatment of distant metastases of differentiated thyroid carcinoma. <i>Journal of Endocrinological Investigation</i> , 1995, 18, 170-172.	1.8	17
38	EXTERNAL RADIATION THERAPY IN THE TREATMENT OF THYROID MALIGNANCY. <i>Endocrinology and Metabolism Clinics of North America</i> , 1996, 25, 141-157.	1.2	50
39	Establishment of anaplastic thyroid carcinoma cell lines useful for analysis of chemosensitivity and carcinogenesis.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 3547-3552.	1.8	19
40	Anaplastic carcinoma of the thyroid. <i>Annals of Oncology</i> , 1996, 7, 739-744.	0.6	17

#	ARTICLE	IF	CITATIONS
41	Conversion of Non-Iodine-Concentrating Differentiated Thyroid Carcinoma Metastases into Iodine-Concentrating Foci after Anticancer Chemotherapy. <i>Thyroid</i> , 1997, 7, 63-66.	2.4	29
42	Therapeutic efficacy of the angiogenesis inhibitor O- (Chloroacetyl- carbamoyl) fumagillol (TNP-470); Tj ETQq1 1 0.784314 rgBT /Over Pathology, 1997, 49, 239-247.	2.1	26
43	Papillary and Follicular Thyroid Carcinoma. <i>New England Journal of Medicine</i> , 1998, 338, 297-306.	13.9	1,422
44	Drug Therapy Alternatives in the Treatment of Thyroid Cancer. <i>Drugs</i> , 1998, 55, 801-812.	4.9	18
45	Anaplastic Thyroid Carcinoma: Behavior, Biology, and Therapeutic Approaches. <i>Thyroid</i> , 1998, 8, 715-726.	2.4	242
46	Medullary Thyroid Carcinoma. <i>Oncology Research and Treatment</i> , 1998, 21, 334-337.	0.8	1
48	Management of the patient with progressive radioiodine non-responsive disease. , 1999, 16, 34-41.		131
49	Anaplastic thyroid carcinoma: A therapeutic challenge. , 1999, 16, 64-69.		149
50	Immediate Causes of Death in Thyroid Carcinoma: Clinicopathological Analysis of 161 Fatal Cases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 4043-4049.	1.8	226
51	A case of anaplastic thyroid carcinoma surviving disease free for over 2 years. <i>Auris Nasus Larynx</i> , 1999, 26, 217-220.	0.5	2
52	Phase II evaluation of high dose accelerated radiotherapy for anaplastic thyroid carcinoma. <i>Radiotherapy and Oncology</i> , 1999, 50, 33-38.	0.3	67
53	Undifferentiated thyroid carcinoma. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2000, 8, 113-116.	0.8	1
54	Anaplastic thyroid carcinoma: Current diagnosis and treatment. <i>Annals of Oncology</i> , 2000, 11, 1083-1090.	0.6	182
55	The management of metastatic differentiated thyroid carcinoma. , 2000, 1, 165-171.		14
56	Northern Cancer Network Guidelines for Management of Thyroid Cancer. <i>Clinical Oncology</i> , 2000, 12, 373-391.	0.6	2
57	Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. <i>British Journal of Cancer</i> , 2000, 83, 715-718.	2.9	119
58	Papillary thyroid cancer. <i>Current Treatment Options in Oncology</i> , 2000, 1, 329-338.	1.3	6
59	Medullary thyroid cancer. <i>Current Treatment Options in Oncology</i> , 2000, 1, 359-367.	1.3	61

#	ARTICLE	IF	CITATIONS
61	Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group Study (E1385). <i>Medical Oncology</i> , 2000, 17, 47-51.	1.2	24
62	Treatment of Anaplastic Thyroid Carcinoma with Paclitaxel: Phase 2 Trial Using Ninety-Six-hour Infusion. <i>Thyroid</i> , 2000, 10, 587-594.	2.4	287
63	A multimodality therapeutic approach in anaplastic thyroid carcinoma: Study on 39 patients. <i>Journal of Endocrinological Investigation</i> , 2000, 23, 755-761.	1.8	61
64	Papillary and follicular thyroid carcinoma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2000, 14, 601-613.	2.2	59
65	Effect of primary treatment on survival in anaplastic thyroid carcinoma. <i>European Journal of Surgical Oncology</i> , 2001, 27, 260-264.	0.5	111
66	Medikamentöse Therapie beim medullären Schilddrüsenkarzinom. , 0, , .		1
67	Prognostic Factors and Therapeutic Strategy for Anaplastic Carcinoma of the Thyroid. <i>World Journal of Surgery</i> , 2001, 25, 617-622.	0.8	182
68	The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours. <i>Clinical Endocrinology</i> , 2001, 55, 575-587.	1.2	45
69	Differentiated thyroid carcinoma in the elderly. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 38, 79-91.	2.0	24
70	Current approaches and perspectives in the therapy of medullary thyroid carcinoma. <i>Cancer</i> , 2001, 91, 1797-1808.	2.0	111
71	Treatment of medullary thyroid carcinoma: an update.. <i>Endocrine-Related Cancer</i> , 2001, 8, 135-147.	1.6	77
72	Construction of Gene Therapy Vectors Targeting Thyroid Cells: Enhancement of Activity and Specificity with Histone Deacetylase Inhibitors and Agents Modulating the Cyclic Adenosine 3',5'-Monophosphate Pathway and Demonstration of Activity in Follicular and Anaplastic Thyroid Carcinoma Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 834-840.	1.8	22
73	Low Concentrations of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Increase Expression of the Na <sup>+</sup> /I <sup>-</sup> Symporter and Iodine Accumulation in Poorly Differentiated Thyroid Carcinoma Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3430-3435.	1.8	144
74	Current Controversies in the Management of Pediatric Patients with Well-Differentiated Nonmedullary Thyroid Cancer: A Review. <i>Thyroid</i> , 2002, 12, 683-702.	2.4	189
75	Cytotoxic Effects of Carboplatinum and Epirubicin in the Setting of an Elevated Serum Thyrotropin for Advanced Poorly Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 4160-4165.	1.8	90
76	Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics. <i>Annals of Oncology</i> , 2002, 13, 1810-1818.	0.6	12
77	Recurrent and/or metastatic thyroid cancer: therapeutic options. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 939-947.	0.9	9
78	Adenovirus HSV-TK construct with thyroid-specific promoter: Enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the camp pathway. <i>International Journal of Cancer</i> , 2002, 99, 453-459.	2.3	19

#	ARTICLE	IF	CITATIONS
79	Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma. <i>Cancer</i> , 2002, 94, 51-61.	2.0	30
80	Chemo-radionuclide therapy for thyroid cancer: Initial experimental study with cultured cells. <i>Annals of Nuclear Medicine</i> , 2002, 16, 403-408.	1.2	6
81	Well-differentiated carcinoma of the thyroid. <i>Otolaryngologic Clinics of North America</i> , 2003, 36, 73-90.	0.5	18
82	Anaplastic thyroid cancer. <i>Current Opinion in Oncology</i> , 2003, 15, 78-83.	1.1	157
84	Current Strategies for Surgical Management and Adjuvant Treatment of Childhood Papillary Thyroid Carcinoma. <i>World Journal of Surgery</i> , 2004, 28, 1187-1198.	0.8	108
85	Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 1137-1143.	0.4	198
86	The management of advanced thyroid cancer. <i>Clinical Oncology</i> , 2004, 16, 561-568.	0.6	45
87	Effect of sodium butyrate on doxorubicin resistance and expression of multidrug resistance genes in thyroid carcinoma cells. <i>Anti-Cancer Drugs</i> , 2005, 16, 255-261.	0.7	17
88	Cerebellar Metastasis as First Metastasis from Papillary Thyroid Carcinoma. <i>Endocrine Journal</i> , 2005, 52, 653-657.	0.7	31
89	Cisplatin-induced genes as potential markers for thyroid cancer. <i>Cellular and Molecular Life Sciences</i> , 2005, 62, 53-64.	2.4	20
90	Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 585-590.	1.2	37
92	Virus-Mediated Oncolysis of Thyroid Cancer by a Replication-Selective Adenovirus Driven by a Thyroglobulin Promoter-Enhancer Region. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3440-3448.	1.8	6
94	Anaplastic (undifferentiated) thyroid cancer: improved insight and therapeutic strategy into a highly aggressive disease. <i>Journal of Laryngology and Otology</i> , 2005, 119, 585-591.	0.4	48
95	Oxaliplatin (Eloxatin®, <sup>©</sup> ) Plus Irinotecan Combination Chemotherapy Found Effective in Refractory Metastatic Insular Thyroid Carcinoma. <i>Thyroid</i> , 2005, 15, 614-617.	2.4	3
97	Non-surgical Management of Thyroid Cancer. , 2006, , 171-191.		12
98	Dexamethasone inhibits TRAIL-induced apoptosis of thyroid cancer cells via Bcl-xL induction. <i>European Journal of Cancer</i> , 2006, 42, 3287-3293.	1.3	45
99	Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2892-2899.	1.8	1,334
100	Indication and Timing of Thyroid Surgery for Patients with Hereditary Medullary Thyroid Cancer Syndromes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 139-147.	2.3	31

#	ARTICLE	IF	CITATIONS
101	Poorly Differentiated and Anaplastic Thyroid Cancer. <i>Cancer Control</i> , 2006, 13, 119-128.	0.7	177
102	Clinical Trials for Thyroid Carcinoma: Past, Present, and Future. , 2006, , 429-434.		0
103	Iodine-Refractory Thyroid Carcinoma. <i>Reviews on Recent Clinical Trials</i> , 2006, 1, 133-141.	0.4	5
104	New molecular targeted therapies in thyroid cancer. <i>Anti-Cancer Drugs</i> , 2006, 17, 869-879.	0.7	21
105	Anaplastic Thyroid Carcinoma: Biology, Pathogenesis, Prognostic Factors, and Treatment Approaches. <i>Annals of Surgical Oncology</i> , 2006, 13, 453-464.	0.7	391
106	Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. <i>Cancer</i> , 2006, 107, 1786-1792.	2.0	105
107	Anaplastic thyroid cancer and primary thyroid lymphoma: A review of these rare thyroid malignancies. <i>Journal of Surgical Oncology</i> , 2006, 94, 725-736.	0.8	96
108	Medullary Thyroid Cancer: Options for Systemic Therapy of Metastatic Disease?. <i>Journal of Clinical Oncology</i> , 2006, 24, 1653-1655.	0.8	30
109	Phase II Study of Celecoxib in Metastatic Differentiated Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2201-2204.	1.8	54
110	Annexin-1 downregulation in thyroid cancer correlates to the degree of tumour differentiation. <i>Cancer Biology and Therapy</i> , 2006, 5, 643-647.	1.5	52
111	Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti- $\alpha$ -Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 1705-1711.	0.8	231
112	Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude Mice. <i>Clinical Cancer Research</i> , 2006, 12, 600-607.	3.2	91
113	Chemoembolization for Liver Metastases from Medullary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2496-2499.	1.8	110
114	Chemotherapy for Anaplastic Thyroid Cancer. , 2006, , 643-646.		1
115	Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. <i>Endocrine-Related Cancer</i> , 2006, 13, 797-826.	1.6	162
116	Capecitabine Therapy for Refractory Metastatic Thyroid Carcinoma: A Case Series. <i>Thyroid</i> , 2006, 16, 801-810.	2.4	18
117	The Tyrosine Kinase Inhibitor, AZD2171, Inhibits Vascular Endothelial Growth Factor Receptor Signaling and Growth of Anaplastic Thyroid Cancer in an Orthotopic Nude Mouse Model. <i>Clinical Cancer Research</i> , 2007, 13, 4519-4527.	3.2	39
118	Quantitative Measurement of Anti-TSH Receptor Antibodies is Useful for the Evaluation of Treatment Effect. <i>Thyroid</i> , 2007, 17, 85-86.	2.4	3

#	ARTICLE	IF	CITATIONS
119	Non-Islet Cell Tumor Hypoglycemia in a Patient with Poorly Differentiated Thyroid Cancer. <i>Thyroid</i> , 2007, 17, 84-85.	2.4	2
120	Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1785-1792.	1.9	129
121	New therapeutic approaches for metastatic thyroid carcinoma. <i>Lancet Oncology</i> , The, 2007, 8, 148-156.	5.1	136
122	High Energy Shock Waves Activate 5-aminolevulinic Acid and Increase Permeability to Paclitaxel: Antitumor Effects of a New Combined Treatment on Anaplastic Thyroid Cancer Cells. <i>Thyroid</i> , 2007, 17, 91-99.	2.4	21
123	Prognostic factors for Korean patients with anaplastic thyroid carcinoma. <i>Head and Neck</i> , 2007, 29, 765-772.	0.9	93
124	New trends in the treatment of undifferentiated carcinomas of the thyroid. <i>Langenbeck's Archives of Surgery</i> , 2007, 392, 397-404.	0.8	27
125	A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. <i>Investigational New Drugs</i> , 2008, 26, 183-188.	1.2	45
126	Guidelines for radioiodine therapy of differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1941-1959.	3.3	593
127	Treatment Outcomes in Anaplastic Thyroid Carcinoma: Survival Improvement in Young Patients With Localized Disease Treated by Combination of Surgery and Radiotherapy. <i>Annals of Surgical Oncology</i> , 2008, 15, 2500-2505.	0.7	99
128	Anaplastic Thyroid Cancer. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008, 37, 525-538.	1.2	162
129	Medical Management of Persistent or Recurrent Differentiated Thyroid Carcinoma. <i>Otolaryngologic Clinics of North America</i> , 2008, 41, 1241-1260.	0.5	1
130	New Agents in the Treatment for Malignancies of the Salivary and Thyroid Glands. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 1279-1295.	0.9	8
131	Early Clinical Studies of Novel Therapies for Thyroid Cancers. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008, 37, 511-524.	1.2	47
133	Phase II Trial of Sorafenib in Advanced Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4714-4719.	0.8	615
134	Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4708-4713.	0.8	593
135	Bone metastases from differentiated thyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2008, 15, 37-49.	1.6	200
136	New therapeutic approaches to treat medullary thyroid carcinoma. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 22-32.	2.9	161
137	Synergy of a Herpes Oncolytic Virus and Paclitaxel for Anaplastic Thyroid Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 1519-1528.	3.2	57

#	ARTICLE	IF	CITATIONS
138	Refractory Thyroid Cancer: A Paradigm Shift in Treatment Is Not Far Off. <i>Journal of Clinical Oncology</i> , 2008, 26, 4701-4704.	0.8	56
139	Oncolytic Vaccinia Virotherapy of Anaplastic Thyroid Cancer <i>in Vivo</i> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4403-4407.	1.8	54
140	A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer. <i>Thyroid</i> , 2008, 18, 317-323.	2.4	185
141	Where Do We Stand with Targeted Therapy of Refractory Thyroid Cancer? Utility of RECIST Criteria. <i>Thyroid</i> , 2008, 18, 279-280.	2.4	8
142	Treatment of recurrent thyroid cancers " is there a light in the horizon?. <i>Current Opinion in Oncology</i> , 2008, 20, 245-248.	1.1	4
143	Treatment of Anaplastic Thyroid Cancer: Is there a Role for PPAR-γ Agonists?. <i>Recent Patents on Endocrine, Metabolic &amp; Immune Drug Discovery</i> , 2008, 2, 194-199.	0.7	0
144	Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. <i>Anti-Cancer Drugs</i> , 2008, 19, 547-552.	0.7	48
145	Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer. <i>Core Evidence</i> , 2009, 4, 43.	4.7	10
146	Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2009, 53, 884-887.	1.3	121
148	Targeted molecular therapies in thyroid carcinoma. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2009, 53, 1061-1073.	1.3	11
149	Clinical Trials for Progressive Differentiated Thyroid Cancer: Patient Selection, Study Design, and Recent Advances. <i>Thyroid</i> , 2009, 19, 1393-1400.	2.4	80
150	New therapeutic advances in the management of progressive thyroid cancer. <i>Endocrine-Related Cancer</i> , 2009, 16, 715-731.	1.6	42
151	Phase I Clinical Trials in 56 Patients with Thyroid Cancer: The M. D. Anderson Cancer Center Experience. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4423-4432.	1.8	32
152	Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. <i>Endocrine-Related Cancer</i> , 2009, 16, 17-44.	1.6	348
153	New targets and therapeutic approaches for endocrine malignancies. <i>Journal of Endocrinology</i> , 2009, 123, 117-141.		97
154	[ <sup>90</sup> Yttrium-DOTA]TOC response is associated with survival benefit in iodine-refractory thyroid cancer. <i>Cancer</i> , 2009, 115, 2052-2062.	2.0	46
155	Targeted therapies in thyroid cancer. <i>Targeted Oncology</i> , 2009, 4, 275-285.	1.7	2
156	Axitinib "a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. <i>Targeted Oncology</i> , 2009, 4, 297-305.	1.7	80

#	ARTICLE	IF	CITATIONS
157	13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study. <i>Thyroid Research</i> , 2009, 2, 8.	0.7	51
159	The Role of Radiation Therapy in the Treatment of Medullary Thyroid Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 532-541.	2.3	21
160	Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature. <i>Endocrine</i> , 2010, 37, 6-10.	1.1	9
161	Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer. <i>Cancer</i> , 2010, 116, 1118-1125.	2.0	19
162	Anaplastic Thyroid Carcinoma: Pathogenesis and Emerging Therapies. <i>Clinical Oncology</i> , 2010, 22, 486-497.	0.6	364
163	Cytotoxic Chemotherapy for Differentiated Thyroid Carcinoma. <i>Clinical Oncology</i> , 2010, 22, 464-468.	0.6	121
164	Molecular Targeted Therapies for Patients with Refractory Thyroid Cancer. <i>Clinical Oncology</i> , 2010, 22, 448-455.	0.6	21
165	Molecular and Other Novel Advances in Treatment of Metastatic Epithelial and Medullary Thyroid Cancers. <i>Journal of Oncology</i> , 2010, 2010, 1-7.	0.6	8
166	Current and Future Perspectives in Thyroid Carcinoma Treatment. <i>European Endocrinology</i> , 2010, 9, 22.	0.8	0
167	Standard and Emerging Therapies for Metastatic Differentiated Thyroid Cancer. <i>Oncologist</i> , 2010, 15, 146-156.	1.9	68
168	Targeting Vascular Endothelial Growth Factor Receptor in Thyroid Cancer: The Intracellular and Extracellular Implications. <i>Clinical Cancer Research</i> , 2010, 16, 778-783.	3.2	33
169	Induction Chemotherapy with Weekly Paclitaxel Administration for Anaplastic Thyroid Carcinoma. <i>Thyroid</i> , 2010, 20, 7-14.	2.4	132
170	Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1545-1557.	1.1	13
171	The Feasibility Study of Docetaxel in Patients with Anaplastic Thyroid Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 596-599.	0.6	45
172	Anaplastic and Poorly Differentiated Thyroid Carcinoma: Therapeutic Strategies and Treatment Outcome of 52 Consecutive Patients. <i>Oncology</i> , 2010, 79, 400-408.	0.9	58
173	Chemotherapy with Paclitaxel and Gemcitabine in Progressive Medullary and Thyroid Carcinoma of the Follicular Epithelium. <i>Hormone and Metabolic Research</i> , 2010, 42, 61-64.	0.7	22
174	Angiogenesis-inhibitors for metastatic thyroid cancer. <i>The Cochrane Library</i> , 2010, , CD007958.	1.5	10
175	Multikinase inhibitors in thyroid cancer. <i>European Journal of Cancer</i> , 2010, 46, 1012-1018.	1.3	14

#	ARTICLE	IF	CITATIONS
176	Axitinib (AG-013736). Recent Results in Cancer Research, 2010, 184, 33-44.	1.8	50
177	BRAF Mutation in Papillary Thyroid Carcinoma: Pathogenic Role and Clinical Implications. Journal of the Chinese Medical Association, 2010, 73, 113-128.	0.6	114
178	Tumeurs atypiques de la thyroïde et formes réfractaires. , 2010, , 451-457.		1
179	Cancer mammaire. , 2010, , 459-465.		0
180	Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence. Clinical Investigation, 2011, 1, 241-253.	0.0	3
181	Response to Sorafenib at a Low Dose in Patients with Radioiodine-Refractory Pulmonary Metastases from Papillary Thyroid Carcinoma. Thyroid, 2011, 21, 119-124.	2.4	51
182	Alternative Therapeutic Approaches in the Treatment of Primary and Secondary Dedifferentiated and Medullary Thyroid Carcinoma. Seminars in Nuclear Medicine, 2011, 41, 139-148.	2.5	15
183	Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment. Journal of Oncology, 2011, 2011, 1-13.	0.6	225
184	Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma. Brazilian Journal of Medical and Biological Research, 2011, 44, 73-77.	0.7	11
185	Insular Variant of Poorly Differentiated Thyroid Carcinoma. Endocrine Practice, 2011, 17, 115-121.	1.1	8
186	SEOM clinical guidelines for the treatment of thyroid cancer. Clinical and Translational Oncology, 2011, 13, 574-579.	1.2	14
187	Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer, 2011, 11, 469.	1.1	81
188	Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Medullary and Differentiated Thyroid Malignancies. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 997-1005.	1.8	100
190	Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer. Journal of Clinical Oncology, 2011, 29, 2660-2666.	0.8	504
191	Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options. World Journal of Clinical Oncology, 2011, 2, 150.	0.9	86
192	Retinoic acid therapy in patients with radioiodine negative differentiated thyroid cancer and clinical or biochemical evidence of disease: An initial experience. Indian Journal of Nuclear Medicine, 2011, 26, 144.	0.1	10
193	Thyroid cancer: pathogenesis and targeted therapy. Therapeutic Advances in Endocrinology and Metabolism, 2011, 2, 173-195.	1.4	53
194	Cancer de la thyroïde. , 2011, , 680-686.		0

#	ARTICLE	IF	CITATIONS
195	A Novel Chemo-radiotherapy with Low-dose Daily Cisplatin, 5-Fluorouracil and Doxorubicin for Anaplastic Thyroid Carcinoma: A Preliminary Report. Japanese Journal of Clinical Oncology, 2011, 41, 1074-1078.	0.6	10
196	Anaplastic Thyroid Carcinoma. Frontiers in Endocrinology, 2012, 3, 84.	1.5	26
198	Treatment of Progressive Dedifferentiated and Medullary Thyroid Cancer with Radiolabeled Somatostatin Analogs. Medical Radiology, 2012, , 323-332.	0.0	0
200	Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary. Clinical Cancer Research, 2012, 18, 3722-3730.	3.2	127
201	2012 European Thyroid Association Guidelines for Metastatic Medullary Thyroid Cancer. European Thyroid Journal, 2012, 1, 5-14.	1.2	137
202	Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies. Journal of Thyroid Research, 2012, 2012, 1-10.	0.5	48
203	Approach to the Patient with Anaplastic Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2566-2572.	1.8	84
204	Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements. Clinical Cancer Research, 2012, 18, 2056-2065.	3.2	141
205	American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid, 2012, 22, 1104-1139.	2.4	717
206	A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3179-3184.	1.8	148
207	Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. Expert Review of Endocrinology and Metabolism, 2012, 7, 541-554.	1.2	42
208	Carcinoma anaplastico della tiroide. L Endocrinologo, 2012, 13, 216-220.	0.0	0
209	ENDOCRINE TUMOURS: Approach to the patient with advanced differentiated thyroid cancer. European Journal of Endocrinology, 2012, 166, 5-11.	1.9	104
210	Unusual Short-Term Complete Response to Two Regimens of Cytotoxic Chemotherapy in a Patient with Poorly Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3046-3050.	1.8	18
211	Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. Expert Review of Anticancer Therapy, 2012, 12, 1137-1147.	1.1	54
212	GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma. Medical Oncology, 2012, 29, 1421-1428.	1.2	35
213	Sorafenib in thyroid cancerâ€”a retrospective case series. Memo - Magazine of European Medical Oncology, 2012, 5, 246-249.	0.3	0
215	Thyroid Neoplasm. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
216	Evaluation of Patients with Disseminated or Locoregionally Advanced Thyroid Cancer: A Primer for Medical Oncologists. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 384-388.	1.8	3
217	Emerging role of multikinase inhibitors for refractory thyroid cancer. <i>Biologics: Targets and Therapy</i> , 2012, 6, 257.	3.0	9
218	Novel molecular targeted therapies for refractory thyroid cancer. <i>Head and Neck</i> , 2012, 34, 736-745.	0.9	23
219	Multimodality therapeutic outcomes In anaplastic thyroid carcinoma: Improved survival in subgroups of patients with localized primary tumors. <i>Head and Neck</i> , 2012, 34, 230-237.	0.9	92
220	Treatment of Thyroid Tumor. , 2013, , .		9
221	Surgery and survival outcomes of 22 patients with epidural spinal cord compression caused by thyroid tumor spinal metastases. <i>European Spine Journal</i> , 2013, 22, 569-576.	1.0	18
222	Candidate Agents for Papillary Thyroid Cancer Identified by Gene Expression Analysis. <i>Pathology and Oncology Research</i> , 2013, 19, 597-604.	0.9	3
224	Chemoradiation in anaplastic thyroid carcinomas. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 86, 290-301.	2.0	32
225	New developments in the diagnosis and treatment of thyroid cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2013, 63, 373-394.	157.7	244
226	Thyroid and Parathyroid Tumors. , 2013, , 297-361.		0
227	Radioiodine Therapy of Differentiated Thyroid Cancer. , 2013, , 133-153.		0
228	Clinical, Safety, and Economic Evidence in Radioactive Iodineâ€“Refractory Differentiated Thyroid Cancer: A Systematic Literature Review. <i>Thyroid</i> , 2013, 23, 392-407.	2.4	61
229	CQ29. Is Chemotherapy Effective for Advanced or Relapsed Medullary Carcinoma?. , 2013, , 171-174.		0
230	CQ53. Is Chemotherapy for Advanced Thyroid Carcinoma Effective?. , 2013, , 299-300.		0
231	Evolving Approaches to Patients with Advanced Differentiated Thyroid Cancer. <i>Endocrine Reviews</i> , 2013, 34, 439-455.	8.9	105
232	Antitumor activity of <i>Pulsatilla koreana</i> extract in anaplastic thyroid cancer via apoptosis and anti-angiogenesis. <i>Molecular Medicine Reports</i> , 2013, 7, 26-30.	1.1	19
233	Treatment and Prognosis of Anaplastic Thyroid Carcinoma: Experience from a Single Institution in China. <i>PLoS ONE</i> , 2013, 8, e80011.	1.1	33
234	Cisplatin based chemotherapy in patients with advanced differentiated thyroid carcinoma refractory to I131 treatment. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2013, 34, 234-237.	0.1	7

#	ARTICLE	IF	CITATIONS
235	Aggressive Multimodal Approach for Anaplastic Thyroid Cancer and Long-Term Survival. Case Reports in Oncological Medicine, 2013, 2013, 1-3.	0.2	4
236	Occult Multifocal Papillary Thyroid Microcarcinoma Presenting as a Supraclavicular Mass Containing Anaplastic Thyroid Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2013, 139, 415.	1.2	6
237	Hedgehog Signaling in Human Medullary Thyroid Carcinoma: A Novel Signaling Pathway. Thyroid, 2013, 23, 1119-1126.	2.4	21
238	Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. Future Oncology, 2013, 9, 1083-1092.	1.1	76
239	Vandetanib for aggressive and symptomatic medullary thyroid cancer. Clinical Practice (London, England), 2013, 10, 101-106.	0.1	0
240	The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer. OncoTargets and Therapy, 2013, 9, 1231.	1.0	39
241	A. Endocrine Neoplasms of the Head and Neck: Medullary Thyroid Carcinoma II. , 2013, , .		0
242	A. Endocrine Neoplasms of the Head and Neck: Anaplastic Carcinoma of the Thyroid. , 2013, , .		0
243	Sorafenib and thyroid cancer. Expert Review of Endocrinology and Metabolism, 2014, 9, 561-570.	1.2	29
244	Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Therapeutic Advances in Medical Oncology, 2014, 6, 267-279.	1.4	63
245	Anaplastic thyroid carcinoma with diffuse thoracic skin metastasis: A case report. Oncology Letters, 2014, 7, 1767-1770.	0.8	5
246	Medical management of metastatic medullary thyroid cancer. Cancer, 2014, 120, 3287-3301.	2.0	38
247	An update on clinical trials of targeted therapies in thyroid cancer. Current Opinion in Oncology, 2014, 26, 36-44.	1.1	24
248	Sorafenib: is a partial response and stabilization of disease greater than 70% a modest response?. Endocrine-Related Cancer, 2014, 21, L1-L2.	1.6	6
249	Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid cancer: A pilot study. Molecular and Clinical Oncology, 2014, 2, 87-92.	0.4	11
250	Thyroid cancer. Current Problems in Cancer, 2014, 38, 48-74.	1.0	36
252	Obatocox overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression. Endocrine-Related Cancer, 2014, 21, 755-767.	1.6	27
253	Evolving Approaches in Managing Radioactive Iodine-Refractory Differentiated Thyroid Cancer. Endocrine Practice, 2014, 20, 263-275.	1.1	21

#	ARTICLE	IF	CITATIONS
254	Expression of cancer stem cell markers is more frequent in anaplastic thyroid carcinoma compared to papillary thyroid carcinoma and is related to adverse clinical outcome. <i>Journal of Clinical Pathology</i> , 2014, 67, 125-133.	1.0	38
255	Guidelines for the management of thyroid cancer. <i>Clinical Endocrinology</i> , 2014, 81, 1-122.	1.2	961
256	Predicting cooperative drug effects through the quantitative cellular profiling of response to individual drugs. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2014, 3, 1-7.	1.3	26
257	The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy. <i>BMC Cancer</i> , 2015, 15, 984.	1.1	55
258	Follicular cell-derived thyroid cancer. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15077.	18.1	88
259	New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas. <i>Anti-Cancer Drugs</i> , 2015, 26, 689-697.	0.7	10
260	Metastatic medullary thyroid cancer: a dramatic response to a systemic chemotherapy (temozolomide) Tj ETQq0 0,0 rBT /Overlock 10	1.0	11
261	Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments. <i>Journal of Thyroid Research</i> , 2015, 2015, 1-8.	0.5	14
262	Chemosensitivity of Anaplastic Thyroid Cancer Based on a Histoculture Drug Response Assay. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-9.	0.6	5
263	Retrospective Study of Sirolimus and Cyclophosphamide in Patients with Advanced Differentiated Thyroid Cancers. <i>Journal of Thyroid Disorders &amp; Therapy</i> , 2015, 04, .	0.1	10
264	Cabozantinib: an orphan drug for thyroid cancer. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1469-1477.	0.5	1
265	Prognostic value of positron emission tomography-assessed tumor heterogeneity in patients with thyroid cancer undergoing treatment with radiopeptide therapy. <i>Nuclear Medicine and Biology</i> , 2015, 42, 349-354.	0.3	40
266	Medullary Thyroid Cancer. , 2015, , 389-401.		0
267	Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-“Rearranged Anaplastic Thyroid Carcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, e84-e87.	0.8	108
268	Management of Thyroid Cancer. <i>Head and Neck Cancer Clinics</i> , 2015, , .	0.0	1
269	Targeted therapies in advanced differentiated thyroid cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 690-698.	3.4	61
270	Four Difficult Thyroid Cancer Cases: Incorporating Medical Therapies. <i>Seminars in Oncology</i> , 2015, 42, e83-e98.	0.8	0
271	Targeted therapy: A new hope for thyroid carcinomas. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 55-63.	2.0	39

#	ARTICLE	IF	CITATIONS
272	Chemotherapy for anaplastic thyroid cancer using docetaxel and cisplatin: report of eight cases. <i>Surgery Today</i> , 2015, 45, 221-226.	0.7	21
273	Complete response to weekly carboplatin+docetaxel chemotherapy in a 91-year-old woman with anaplastic thyroid cancer. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2015, 36, 268-272.	0.6	3
274	Influence of risk grouping on therapeutic decisions in patients with anaplastic thyroid carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2015, 272, 985-993.	0.8	4
275	Nontoxic Diffuse Goiter, Nodular Thyroid Disorders, and Thyroid Malignancies. , 2016, , 449-488.		5
276	Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. <i>Drug Design, Development and Therapy</i> , 2016, 10, 873.	2.0	33
277	12 Thyroid diseasesmedical managementcancer, medullaryThyroid diseasesmedical managementof cancer, anaplastic thyroidMedullary thyroid cancers (MTCs)medical management ofDiseases, thyroidmedical managementof cancer, medullaryDiseases, thyroidmedical managementof cancer, anaplastic thyroidAnaplastic thyroid cancers (ATCs)medical management ofMedical Management of <i>Medullary and Anaplastic Thyroid Cancers</i> , 2016, , .		0
278	Neoadjuvant Therapy in Differentiated Thyroid Cancer. <i>International Journal of Surgical Oncology</i> , 2016, 2016, 1-8.	0.3	10
279	Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 30.	1.3	23
281	The Management of Thyroid and Parathyroid Cancer. , 2016, , 673-692.		0
282	Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression. <i>Endocrine Pathology</i> , 2016, 27, 312-324.	5.2	30
283	Multitargeted Kinase Inhibition in Metastatic Differentiated Radioiodine-Refractory Thyroid Cancer: A Look at New Therapeutic Options for a Rare Disease. <i>Oncology Research and Treatment</i> , 2016, 39, 548-552.	0.8	4
284	External Radiation Therapy for Medullary Cancer. , 2016, , 887-890.		0
285	Anaplastic thyroid carcinoma: Failure of conventional therapy but hope of targeted therapy. <i>Head and Neck</i> , 2016, 38, E1122-9.	0.9	10
286	Remarkable response in 2 cases of Advanced Poorly Differentiated Thyroid Carcinoma with liposomal doxorubicin plus cisplatin. <i>Cancer Biology and Therapy</i> , 2016, 17, 693-697.	1.5	7
287	Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy. <i>Journal of Oncology Practice</i> , 2016, 12, 511-518.	2.5	81
288	Increased rates of advanced thyroid cancer in California. <i>Journal of Surgical Research</i> , 2016, 201, 244-252.	0.8	11
289	pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer. <i>Hormones and Cancer</i> , 2016, 7, 188-195.	4.9	11
290	Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review. <i>Endocrine-Related Cancer</i> , 2016, 23, R71-R84.	1.6	43

#	ARTICLE	IF	CITATIONS
291	Management of advanced medullary thyroid cancer. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 64-71.	5.5	100
292	The Role of Targeted Therapies or Nonsurgical Treatment of Thyroid Malignancies: Is Surgery Being Replaced?. , 2016, , 203-228.		0
294	Rare Thyroid Malignancies: an Overview for the Oncologist. <i>Clinical Oncology</i> , 2017, 29, 298-306.	0.6	19
295	Management of Thyroid Nodules and Differentiated Thyroid Cancer. , 2017, , .		4
297	Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1943-1950.	1.8	86
298	Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 335-347.	2.2	38
299	Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma. <i>Thyroid</i> , 2017, 27, 1142-1148.	2.4	67
300	Unusual presentation of anaplastic thyroid carcinoma with diffuse neck and thoracic nodules and hyperthyroidism. <i>Dermatologica Sinica</i> , 2017, 35, 85-87.	0.2	5
301	Systemic Therapy for Advanced Metastatic Thyroid Cancer. , 2017, , 433-450.		0
302	Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4506-4514.	1.8	86
303	Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. <i>Nature Reviews Endocrinology</i> , 2017, 13, 644-660.	4.3	324
304	Apatinib Inhibits Angiogenesis Via Suppressing Akt/GSK3 $\beta$ /ANG Signaling Pathway in Anaplastic Thyroid Cancer. <i>Cellular Physiology and Biochemistry</i> , 2017, 44, 1471-1484.	1.1	61
305	Uncommon response of cisplatin and etoposide for treatment of advanced medullary thyroid carcinoma. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 1628-1633.	0.2	2
306	Lenvatinib for Anaplastic Thyroid Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 25.	1.3	141
307	Antitumor activity of fucoidan in anaplastic thyroid cancer via apoptosis and anti-angiogenesis. <i>Molecular Medicine Reports</i> , 2017, 15, 2620-2624.	1.1	24
308	Significant Amelioration of Tracheal Stenosis following Lenvatinib in a Patient Who Has Anaplastic Thyroid Carcinoma with Bronchomediastinal Infiltration: A Case Report. <i>Case Reports in Oncology</i> , 2017, 10, 175-181.	0.3	9
309	Refractory thyroid carcinoma: which systemic treatment to use?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401775285.	1.4	18
310	Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. <i>Thyroid</i> , 2018, 28, 79-87.	2.4	91

#	ARTICLE	IF	CITATIONS
311	Practical Management of Thyroid Cancer. , 2018, , .		4
312	Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2019, 30, 1856-1883.	0.6	592
313	Diagnosis and Management of Anaplastic Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2019, 48, 269-284.	1.2	58
314	Treatment Outcomes in Anaplastic Thyroid Cancer. Journal of Thyroid Research, 2019, 2019, 1-11.	0.5	18
315	Everolimus in Anaplastic Thyroid Cancer: A Case Series. Frontiers in Oncology, 2019, 9, 106.	1.3	25
316	Management of treatment-related toxicities in advanced medullary thyroid cancer. Current Opinion in Oncology, 2019, 31, 236-242.	1.1	7
317	Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2019, 48, 253-268.	1.2	18
318	Cancer of the Endocrine System. , 2020, , 1074-1107.e11.		5
319	Management of Undifferentiated (Anaplastic) Thyroid Cancer. , 2020, , 27-34.		1
320	Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy. International Journal of Molecular Sciences, 2020, 21, 4951.	1.8	7
321	Management of medullary thyroid carcinoma. Annals of Thyroid, 2020, 5, 16-16.	1.0	1
322	Bone metastases in thyroid cancer. Journal of Bone Oncology, 2020, 21, 100282.	1.0	59
323	SEOM clinical guideline thyroid cancer (2019). Clinical and Translational Oncology, 2020, 22, 223-235.	1.2	23
324	The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: Core questions and recommendations for treatments of thyroid cancer. Endocrine Journal, 2020, 67, 669-717.	0.7	96
325	Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer. Endocrine, 2021, 71, 427-433.	1.1	14
326	Anaplastic Thyroid Cancer and Primary Thyroid Lymphoma. , 2021, , 246-254.e3.		0
327	Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics. Current Oncology Reports, 2021, 23, 31.	1.8	28
328	2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid, 2021, 31, 337-386.	2.4	297

#	ARTICLE	IF	CITATIONS
329	Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma. <i>Thyroid</i> , 2021, 31, 1076-1085.	2.4	96
330	Revisiting Combination Chemotherapy as a Single Modality Palliative Therapy for Advanced Anaplastic Thyroid Carcinoma—a Single Institution Experience. <i>Indian Journal of Surgical Oncology</i> , 2022, 13, 208-215.	0.3	2
331	Pathobiology of Antineoplastic Therapy in Undifferentiated Thyroid Cancer. , 2004, 122, 357-367.		2
332	Schilddrüsenkarzinom. , 2006, , 3421-3466.		1
333	Medulläres Schilddrüsenkarzinom. , 2006, , 4071-4091.		3
334	Chemotherapy of Advanced Thyroid Cancer. , 1992, , 204-214.		3
335	Chemotherapy of Anaplastic Thyroid Cancer. , 2000, , 337-340.		3
336	Papillary Carcinoma. , 2006, , 253-260.		2
337	External Radiation Therapy of Medullary Cancer. , 2006, , 605-607.		1
338	Medullary Carcinoma of the Thyroid. , 2006, , 609-611.		1
339	Poorly Differentiated and Undifferentiated Thyroid Cancer. , 2009, , 121-136.		2
340	Thyroid and Parathyroid Carcinoma. , 1989, , 879-896.		2
342	Cancer of the Endocrine System. , 2008, , 1271-1305.		10
343	Cancer of the Thyroid. , 2010, , 726-736.		1
344	Nontoxic Diffuse and Nodular Goiter and Thyroid Neoplasia. , 2011, , 440-475.		12
345	Cancer of the Endocrine System. , 2014, , 1112-1142.e7.		2
346	Thyroid and Parathyroid Cancer. <i>Otolaryngologic Clinics of North America</i> , 1990, 23, 1181-1197.	0.5	2
347	Chemotherapy and Multimodality Treatment in Thyroid Carcinoma. <i>Otolaryngologic Clinics of North America</i> , 1990, 23, 523-527.	0.5	33

#	ARTICLE	IF	CITATIONS
348	2-Deoxy-d-Glucose Can Complement Doxorubicin and Sorafenib to Suppress the Growth of Papillary Thyroid Carcinoma Cells. PLoS ONE, 2015, 10, e0130959.	1.1	19
349	Thyroid nodules - Stepwise diagnosis and management. Hormones, 2007, 6, 101-119.	0.9	74
350	Systemic Therapeutic Approaches to Advanced Thyroid Cancers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 389-392.	1.8	2
351	Systemic Therapeutic Approaches to Advanced Thyroid Cancers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, 32, 389-392.	1.8	1
352	Anaplastic thyroid cancer: How far can we go?. EXCLI Journal, 2020, 19, 800-812.	0.5	7
353	Therapeutic options for advanced thyroid cancer. International Journal of Clinical Endocrinology and Metabolism, 2019, 5, 026-034.	1.2	30
354	Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells. Oncotarget, 2017, 8, 43008-43022.	0.8	16
355	Risk of venous and arterial thromboembolic events associated with tyrosine kinase inhibitors in advanced thyroid cancer: a meta-analysis and systematic review. Oncotarget, 2019, 10, 4205-4212.	0.8	9
356	Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer. Oncotarget, 2015, 6, 9073-9085.	0.8	54
357	Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis. Oncotarget, 2015, 6, 18038-18049.	0.8	23
358	Pretargeted Radioimmunotherapy in the Treatment of Metastatic Medullary Thyroid Cancer. Current Oncology, 2009, 16, 3-8.	0.9	10
359	Lenvatinib vs. palliative therapy for stage IVC anaplastic thyroid cancer. Molecular and Clinical Oncology, 2020, 12, 138-143.	0.4	17
360	CLINICAL EVALUATION OF TREATMENT FOR ANAPLASTIC CARCINOMA OF THE THYROID. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 1998, 59, 1-5.	0.0	1
361	Apigenin Inhibits Thyroid Cancer Cell Growth and Proliferation through Down-Regulation of HIF1 $\alpha$ and VEGF Expression. Indian Journal of Pharmaceutical Education and Research, 2020, 54, 668-673.	0.3	2
362	Kinase inhibitors for advanced medullary thyroid carcinoma. Clinics, 2012, 67, 125-129.	0.6	16
363	Chemotherapy of Differentiated (Papillary or Follicular) Thyroid Carcinoma. , 2000, , 221-223.		1
364	Papillary Carcinoma. , 2000, , 185-192.		0
365	Chemotherapy for Thyroid Cancer. , 2000, , 179-182.		0

#	ARTICLE	IF	CITATIONS
366	Medullary Carcinoma of the Thyroid. , 2000, , 405-408.		0
367	Treatment with Cytotoxic Drugs. , 2001, , 139-151.		2
368	Prognosis of a case with a diffuse sclerosing variant of papillary thyroid carcinoma after treatment with paclitaxel.. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2002, 63, 566-570.	0.0	0
369	Postoperative Adjuvant Therapy and Follow-Up of Thyroid Carcinoma. Taehan Uihak Hyophoe Chi the Journal of the Korean Medical Association, 2004, 47, 1183.	0.1	0
371	Chemotherapy for Thyroid Cancer. , 2006, , 491-493.		0
372	Malignome endokriner Organe. , 2007, , 885-936.		0
373	Using Retinoids to Increase Radioiodine Uptake in Thyroid Cancer. , 2009, , 991-999.		0
375	Differentiated Thyroid Cancers of Follicular Cell Origin. Cancer Treatment and Research, 2010, 153, 35-56.	0.2	1
376	Thyroid Neoplasia. , 2010, , 1668-1701.		1
377	Endokrinologische Erkrankungen. , 2011, , 719-825.		0
379	Targeted Therapy of Thyroid Cancer. Growth Hormone, 2012, , 301-315.	0.2	0
380	Literaturhinweise und Internetadressen. , 2012, , e1-e61.		0
382	Anaplastic Thyroid Carcinoma. , 2012, , 249-258.		0
383	Malignome endokriner Organe. , 2012, , 851-900.		0
384	Evaluation of Protracted Cisplatin Infusion in Advanced Anaplastic Thyroid Cancer. International Journal of Medical Research and Review, 2013, 1, 162-168.	0.1	0
385	Advanced thyroid cancer patients in Phase I clinical trials: Outcome assessment and literature review. World Journal of Oncology, 2014, 5, 24-32.	0.6	0
386	Endokrine Tumoren. , 1986, , 294-304.		0
387	Therapiekonzepte. , 1987, , 1-899.		1

#	ARTICLE	IF	CITATIONS
389	TREATMENTS OF UNDIFFERENTIATED THYROID CARCINOMA AND ITS PROBLEMS. The Journal of the Japanese Practical Surgeon Society, 1991, 52, 1171-1175.	0.0	0
391	Schilddrüsenkarzinom. , 1993, , 279-285.		0
392	Flow-cytophotometric DNA Measurements for Monitoring and Planning Chemotherapy in Anaplastic Thyroid Carcinoma. , 1993, , 107-113.		1
393	Therapie von hochmalignen Schilddrüsentumoren. , 1993, , 358-365.		0
394	Chemotherapy of undifferentiated thyroid cancer (UCT) and sarcoma of the thyroid gland (ST). , 1994, , 295-297.		0
395	Schilddrüsenkarzinome. , 1995, , 404-419.		0
396	A CLINICOPATHOLOGICAL STUDY OF CASES OF DEATHS DUE TO THYROID CANCER. The Journal of the Japanese Practical Surgeon Society, 1995, 56, 480-485.	0.0	0
397	Schilddrüsen. , 1996, , 401-423.		2
398	Medulläres Schilddrüsenkarzinom. , 1997, , 914-930.		0
399	Chemotherapy and Biological Therapy of Thyroid Cancer. Growth Hormone, 1998, , 341-350.	0.2	1
400	Schilddrüsenkarzinome. , 1998, , 476-495.		0
401	MULTIDISCIPLINARY TREATMENT FOR A PATIENT WITH UNDIFFERENTIATED THYROID CANCER. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 1999, 60, 2051-2056.	0.0	0
402	Metronomic chemotherapy in anaplastic thyroid carcinoma: A potentially feasible alternative to therapeutic nihilism. Indian Journal of Palliative Care, 2015, 21, 245.	1.0	5
403	Management of Distant Metastases in Differentiated Thyroid Cancer. Head and Neck Cancer Clinics, 2015, , 61-77.	0.0	0
405	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
406	The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer. KliniĖska ĖksperimentalĖ TiroidologiĖ, 2015, 11, 25.	0.1	2
407	Fifteen-year treatment of metastatic thyroid medullary carcinoma: a case report. The European Research Journal, 2015, 1, 160.	0.1	1
408	Medullary Carcinoma of the Thyroid: Chemotherapy. , 2016, , 891-897.		0

#	ARTICLE	IF	CITATIONS
409	Radionuclide Therapy of Thyroid Tumors. , 2016, , 1-47.		0
410	Chemotherapy of Thyroid Cancer: General Principles. , 2016, , 717-721.		0
411	Chemotherapy for Anaplastic Thyroid Cancer. , 2016, , 947-952.		0
412	EFFICACY AND SAFETY OF MULTI-TARGETED KINASE INHIBITORS IN PROGRESSIVE, RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCERS: A META-ANALYSIS. Journal of Cancer & Allied Specialties, 2016, 2, .	0.1	0
413	Clinical experience in using lenvatinib in patients with progressive, radioactive iodine-refractory differentiated thyroid cancer. Opuholi Golovy I Sei, 2016, 6, 65-69.	0.1	1
414	Management of Rare Thyroid Malignancies. , 0, , .		0
415	Radionuclide Therapy of Thyroid Tumors. , 2017, , 1197-1241.		1
416	Local and Systemic Treatment of Unresectable Disease. , 2017, , 263-280.		0
417	Rapid Recurrence of Anaplastic Carcinoma: Advocacy towards Non-Surgery. Endocrinology&Metabolism International Journal, 2017, 5, .	0.1	0
418	Management of Distant Metastasis in Differentiated Thyroid Cancer. , 2018, , 121-140.		0
419	Anaplastic Thyroid Carcinoma. , 2018, , 151-161.		0
420	Use of Sorafenib for Radioactive Iodine-refractory Differentiated Thyroid Carcinoma. Practica Otologica, Supplement, 2018, 152, 84-85.	0.0	0
421	Anaplastic Thyroid Carcinoma. , 2019, , 359-363.		0
422	A retrospective analysis of efficacy of systemic therapy in metastatic thyroid cancer. Marmara Medical Journal, 0, , 33-37.	0.2	0
423	Hybrid Imaging and Radionuclide Therapy for Thyroid Disorders. , 2019, , 707-747.		0
425	SchilddrÃ¼senkarzinom. , 0, , 524-537.		0
426	Anaplastic Thyroid Carcinoma. , 2007, , 161-170.		0
428	Induction of apoptosis and autophagy in metastatic thyroid cancer cells by valproic acid (VPA). International Journal of Clinical and Experimental Pathology, 2015, 8, 8291-7.	0.5	11

#	ARTICLE	IF	CITATIONS
429	Overall Survival of Patients with Aggressive Thyroid Cancer on Fine-Needle Aspiration Biopsy Examination. A Tertiary Romanian Center Experience. <i>MĂdica</i> , 2015, 10, 221-225.	0.4	0
430	New Treatment Options for Metastatic Thyroid Cancer. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2015, 32, 21S-26S.	0.6	2
431	Evaluation of CYFRA 21.1 as a Dedifferentiation Marker of Advanced Thyroid Cancer. <i>Indian Journal of Nuclear Medicine</i> , 2020, 35, 116-121.	0.1	2
432	A Case of Solitary Metastatic Deposit in the Orbital Rim from Follicular Thyroid Cancer. <i>Korean Society for Head and Neck Oncology</i> , 2021, 37, 105-109.	0.1	0
433	Anaplastic Thyroid Carcinoma: An Update. <i>Cancers</i> , 2022, 14, 1061.	1.7	47
434	Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies. <i>Cancer Treatment Reviews</i> , 2022, 105, 102372.	3.4	13
435	Updates on therapy for medullary thyroid cancer in 2021. <i>Annales D'Endocrinologie</i> , 2022, 83, 114-118.	0.6	4
436	Advances in Biomarker-Driven Targeted Therapies in Thyroid Cancer. <i>Cancers</i> , 2021, 13, 6194.	1.7	4
437	Evaluation of CYFRA 21.1 as a dedifferentiation marker of advanced thyroid cancer. <i>Indian Journal of Nuclear Medicine</i> , 2020, 35, 116.	0.1	2
441	Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 925-951.	2.3	122
442	Role of surgery to the primary tumor in metastatic anaplastic thyroid carcinoma: pooled analysis and SEER-based study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3527-3547.	1.2	4
444	Radionuclide Therapy of Thyroid Tumors. , 2022, , 1381-1429.		0
445	Multiple Endocrine Neoplasia 2a: Case Report and Review of Literature. , 0, , .		0
446	Anaplastic thyroid carcinoma: advances in molecular profiling and targeted therapy. <i>Current Opinion in Oncology</i> , 2023, 35, 1-9.	1.1	7
447	Systemic Therapy in Thyroid Cancer. , 0, , .		0
448	Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer. <i>Thyroid Research</i> , 2023, 16, .	0.7	5
454	Medullary Thyroid Cancer: Diagnosis and Non-surgical Management. , 2023, , 201-214.		0